chellenberg Wittmer advised Santhera Pharmaceuticals on the deal. Swiss Biotech Santhera has entered an exclusive licence agreement with China-based Sperogenix Therapeutics for the development of Vamorolone...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here